Additionally, in MS, evidence on low serum levels of IFN in most patients (9) poses the basis for IFN use in MS treatment and paves the way for the investigation of endogenous defect of IFN signaling in MS. The gene discussed is IFNA1; the disease is myeloid sarcoma.